n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Elan Insanity, Walter's Wild Ride, Pratt's Spat and Oy Vey Orchard highlight Gregg Greenberg's list this week of the Street's dumbest items.

Stock Futures Hold Gains as Inflation Appears Tame

Stock Futures Hold Gains as Inflation Appears Tame

Stock futures remain in the green as the Fed begins its meeting and investors process a moderate inflation report.

Elan Advises Shareholders To Withdraw Any Acceptances Of The Royalty Pharma Offer And Not To Tender Any Further Acceptances Into This Lapsed Offer*

Elan Advises Shareholders To Withdraw Any Acceptances Of The Royalty Pharma Offer And Not To Tender Any Further Acceptances Into This Lapsed Offer*

Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today advises Elan Shareholders to withdraw any acceptances of Royalty Pharma’s Offer without delay and not to tender any further acceptances.

Elan Shareholder Vote Nixes Royalty Pharma Takeover -- For Now

Elan Shareholder Vote Nixes Royalty Pharma Takeover -- For Now

Royalty Pharma is going to court to re-instate its hostile tender offer for Elan following a shareholder vote.

Elan Announces Results Of EGM

Elan Announces Results Of EGM

Elan Corporation, plc (NYSE:ELN) (Elan or the Company) announces that, at its Extraordinary General Meeting held earlier today, shareholders approved the Share Repurchase Program.

Stocks Decline as Tepid Growth Combines With Fed Jitters

Stocks Decline as Tepid Growth Combines With Fed Jitters

Major U.S. stock averages retreated Friday as the market remained skittish amid tepid economic reports.

Elan Plants 'For Sale' Sign on Front Lawn

Elan Plants 'For Sale' Sign on Front Lawn

The latest twist in the contentious battle for Elan as it fights a takeover by Royalty Pharma.

Elan To Proceed With Formal Sale Process

Elan To Proceed With Formal Sale Process

Elan Corporation, plc (NYSE:ELN) (Elan or the Company) today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date.

3 Big Stocks on Traders' Radars

3 Big Stocks on Traders' Radars

Here's a look at how to trade some of the most active stocks on the market today.

Keeping an Eye on the Pros

Today's investment environment has more moving parts than ever.

Stock Futures Pare Losses After Retail Sales Number

Stock Futures Pare Losses After Retail Sales Number

Stock futures continue to point to a lower open after April's retail sales numbers rise.

Dollar Strength Hits Oil, Gold

Dollar Strength Hits Oil, Gold

A strong dollar pulls down oil and gold, as Bloomberg comes under fire for its privacy breach, while Elan and Theravance agree to a deal.

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures point lower ahead of a retail sales report; Elan and Theravance in a $1 billion royalty agreement; Post Holdings and Take-Two report earnings.

Stocks to Watch: Elan, Theravance, Take-Two

Stocks to Watch: Elan, Theravance, Take-Two

Elan and Theravance enter a $1 billion royalty agreement.

Why This Fund Manager Is Short Ziopharm

Why This Fund Manager Is Short Ziopharm

He believes the palifosfamide sarcoma study to be released next week will be a failure.

New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status

New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI ® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS)...

SAC to Pay Record Insider Trading Penalty

SAC to Pay Record Insider Trading Penalty

Two units of SAC Capital Advisors will pay more than $614 million in what federal regulators are calling the largest insider trading settlement ever.

Elan Discloses Filing Of Share Repurchase Tender Offer Documentation

Elan Discloses Filing Of Share Repurchase Tender Offer Documentation

Elan Corporation, plc (NYSE:ELN) (the Company) today disclosed the Tender Offer documentation for the Share Repurchase has been filed and is available on the Company’s website at www.

Dow Sets Another Record as Stocks Rise

Dow Sets Another Record as Stocks Rise

Major U.S. stock averages move higher in late trading on Monday as the Dow ignores worries about the end of its rally.

Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase

Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase

Elan Corporation, plc (NYSE:ELN) (the Company) today provides an update on the Tysabri Restructuring Transaction (“the Tysabri Transaction”) announced on February 6, 2013 and further information regarding the ...

Elan’s Response To Royalty Pharma Statement Of Today

Elan’s Response To Royalty Pharma Statement Of Today

The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges this morning's statement by Royalty Management, LLC (Royalty Pharma).

Elan Announces Further Unlocking Of Value To Benefit Shareholders

Elan Announces Further Unlocking Of Value To Benefit Shareholders

The Board of Elan Corporation, plc (NYSE:ELN) (the Company) has approved the decision to initiate a unique cash dividend policy enabling its shareholders to benefit directly from the long term cash flow generated by...

You Have to Love a Lucrative 'Drug Deal'

You Have to Love a Lucrative 'Drug Deal'

A U.S. pharmaceutical investor just made a $6.55 billion offer that should make markets sit up and take notice.

Elan Announces The Appointment Of Mr. John Given As General Counsel

Elan Announces The Appointment Of Mr. John Given As General Counsel

Elan Corporation, plc (NYSE:ELN) today announced the appointment of Mr.

Elan’s Response To Indication Of Interest

Elan’s Response To Indication Of Interest

The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges this morning's announcement by Royalty Management, LLC (Royalty Pharma) regarding an indicative, conditional, proposal which may or may not lead ...

Royalty Pharma: Don't Let Elan Piss Away $3 Billion on Stupid Acquisitions

Royalty Pharma: Don't Let Elan Piss Away $3 Billion on Stupid Acquisitions

Royalty's $11-per-share takeover bid plays into shareholder fears that Elan will waste its cash windfall.

Elan Provides Update Post Restructuring Announcement Of Tysabri Collaboration

Elan Provides Update Post Restructuring Announcement Of Tysabri Collaboration

Elan Corporation, plc (NYSE:ELN) today provides an update to the market post the February 6, 2013 announcement regarding the restructuring of the Tysabri® collaboration with Biogen Idec.

Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2012

Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2012

Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2012.

2 Hot Stocks to Trade (or Not)

2 Hot Stocks to Trade (or Not)

Here's a look at how to trade some of the most active names on the market today.

Before the Bell: Feb. 6

Before the Bell: Feb. 6

Portfolio manager David Peltier previews Wednesday's trading action.